The Chicago Entrepreneur

Viking Therapeutics stock jumps 16% after drugmaker moves weight loss injection to late-stage trial

It brings the drugmaker one step closer to joining the market for GLP-1s, which analysts say could grow into a $150 billion market by the end of the decade. 

Previous post Dow’s stock dives as a weak economic recovery leads to rare earnings miss
Next post These ‘zombie’ student-loan organizations still have power over borrowers’ lives — and their bank accounts